Activation of autophagy by erlotinib protects NSCLC cells with wild-type EGFR from erlotinib cytotoxicity

被引：1

作者：

Schwartz, Edward L. ^{[1
]}

Ling, Yi-He ^{[1
]}

Zou, Yiyu ^{[1
]}

Piperdi, Bilal ^{[1
]}

Perez-Soler, Roman ^{[1
]}

机构：

[1] Albert Einstein Coll Med, Bronx, NY 10467 USA

来源：

CANCER RESEARCH | 2012年 / 72卷

关键词：

D O I：

10.1158/1538-7445.AM2012-850

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

850

引用

下载

页数：2

共 50 条

[21] Long-Term Survivors with EGFR Wild-Type Advanced NSCLC Treated with Second-Line Erlotinib: Subgroup Analysis from WILT Study
De Castro, Javier
Bernabe, Reyes
Angeles Sala, M.
Puente, Javier
Vazquez, Sergio
Majem, Margarita
Rosario Garcia-Campelo, M.
Paredes, Alfredo
Lopez, Rafael
Girones, Regina
Diz, Pilar
Gomez-Codina, Jose
Triguboff, Alberto
Terrancle, Angeles
Gordo, Rocio
JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S235 - S235
[22] Erlotinib Potentiates Cetuximab-dependent Cell Citotoxicity in Egfr Wild Type Nsclc Cell Lines
Cavazzoni, A.
Alfieri, R. R.
La Monica, S.
Galetti, M.
Bonelli, M.
Fumarola, C.
Galvani, E.
Tiseo, M.
Ardizzoni, A.
Petronini, P. G.
EUROPEAN JOURNAL OF CANCER, 2012, 48 : S246 - S246
[23] Gene Mutation Analysis in EGFR Wild Type NSCLC Responsive to Erlotinib: Are There Features to Guide Patient Selection?
Ulivi, Paola
Delmonte, Angelo
Chiadini, Elisa
Calistri, Daniele
Papi, Maximilian
Mariotti, Marita
Verlicchi, Alberto
Ragazzini, Angela
Capelli, Laura
Gamboni, Alessandro
Puccetti, Maurizio
Dubini, Alessandra
Burgio, Marco Angelo
Casanova, Claudia
Crino, Lucio
Amadori, Dino
Dazzi, Claudio
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2015, 16 (01): : 747 - 757
[24] TAILOR: Phase III trial comparing erlotinib with docetaxel in the second-line treatment of NSCLC patients with wild-type (wt) EGFR.
Garassino, Marina Chiara
Martelli, Olga
Bettini, Anna
Floriani, Irene
Copreni, Elena
Lauricella, Calogero
Ganzinelli, Monica
Marabese, Mirko
Broggini, Massimo
Veronese, Silvio
Gherardi, Giorgio
Longo, Flavia
Fabbri, Maria Agnese
Tomirotti, Maurizio
Alabiso, Oscar
Sarobba, Maria Giuseppa
Labianca, Roberto
Marsoni, Silvia
Farina, Gabriella
Scanni, Alberto
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[25] Phase I/II Study of Intermitted Erlotinib in Combination with Docetaxel in Patients with Recurrent NSCLC with Wild-Type EGFR: WJOG 4708L
Kimura, T.
Kawaguchi, T.
Kudoh, S.
Chiba, Y.
Yoshioka, H.
Watanabe, K.
Kijima, T.
Kogure, Y.
Oguri, T.
Yoshimura, N.
Niwa, T.
Kasai, T.
Hayashi, H.
Ono, A.
Tanaka, H.
Yano, S.
Nakamura, S.
Yamamoto, N.
Nakanishi, Y.
Nakagawa, K.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2129 - S2129
[26] The EGFR Pathway Regulates BCRP Expression in NSCLC Cells: Role of Erlotinib
Porcelli, Letizia
Giovannetti, Elisa
Assaraf, Yehuda G.
Jansen, Gerrit
Scheffer, George L.
Kathman, Ietje
Azzariti, Amalia
Paradiso, Angelo
Peters, Godefridus J.
CURRENT DRUG TARGETS, 2014, 15 (14) : 1322 - 1330
[27] Use of circulating tumor cells as response evaluation criteria to erlotinib treatment in EGFR wild-type metastatic lung cancer patients
Jurado, J. M.
Serrano, M. J.
Valdivia, J.
Mellado, M.
Lorente, J. A.
Delgado, J. R.
Ortega, J. A.
Exposito, J.
Suarez, L.
Garcia-Puche, J. L.
EUROPEAN JOURNAL OF CANCER, 2015, 51 : S647 - S647
[28] EGFR inhibitors for wild-type EGFR NSCLC: to use or not to use?
Jassem, Jacek
Dziadziuszko, Rafal
LANCET ONCOLOGY, 2013, 14 (10): : 916 - 917
[29] The PI3K-Akt signaling leads to synergy of erlotinib and crizotinib in wild-type NSCLC.
Rolfo, Christian Diego
Van der Steen, Nele
Pauwels, Patrick
Reclusa, Pablo
Peters, Godefridus J.
Giovannetti, Elisa
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[30] A multifunctional nanotheranostic agent potentiates erlotinib to EGFR wild-type non-small cell lung cancer
Wang, Duo
Zhou, Jun
Fang, Weimin
Huang, Cuiqing
Chen, Zerong
Fan, Meng
Zhang, Ming-Rong
Xiao, Zeyu
Hu, Kuan
Luo, Liangping
BIOACTIVE MATERIALS, 2022, 13 : 312 - 323

← 1 2 3 4 5 →